FDA conflict-of-interest rules delay drug approval, Republicans say

07/8/2011 | Hill, The

FDA conflict-of-interest rules that limit agency reliance on experts with ties to the drug industry have slowed the drug-approval process and should be loosened, said House Republicans working on an FDA reauthorization bill. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said the rules make it more complicated to find experts to serve on advisory committees.

View Full Article in:

Hill, The

Published in Brief:

SmartBrief Job Listings for Health Care